CLINICAL_TRIALS
trial_result
· 2022-04-21
Clinical Trial Update: Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 [Phase 1]
Summary
Phase 1 trial evaluating PF-04518600 (OX40 agonist) alone and combined with PF-05082566 (4-1BB agonist) in neoplasms; completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2022-04-21